12:00 AM
Jul 24, 2000
 |  BC Week In Review  |  Company News  |  Deals

Discovery Therapeutics, Bayer deal

Discovery acquired from BAYG two Phase II anti-inflammatory compounds, and will develop the lead compound, DTI-0026, an...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >